HALO.O
Latest Trade
47.62USDChange
-0.05(-0.10%)Volume
635,186Today's Range
-
48.5152 Week Range
-
49.02As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 47.67 |
|---|---|
Open | 48.37 |
Volume | 635,186 |
3M AVG Volume | 39.75 |
Today's High | 48.51 |
Today's Low | 46.90 |
52 Week High | 49.02 |
52 Week Low | 12.71 |
Shares Out (MIL) | 135.18 |
Market Cap (MIL) | 6,444.18 |
Forward P/E | 52.20 |
Dividend (Yield %) | -- |
Halozyme Raises Full Year 2020 Guidance
Horizon Therapeutics PLC And Halozyme Therapeutics Inc Enter Global Collaboration And License Agreement For Enhanze Technology
Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo For Her2-Positive Breast Cancer
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Industry
Biotechnology & Drugs
Contact Info
11388 Sorrento Valley Rd
SAN DIEGO, CA
92121-1345
United States
+1.858.7948889
https://www.halozyme.com/Executive Leadership
Connie L. Matsui
Independent Chairman of the Board
Helen I. Torley
President, Chief Executive Officer, Director
Elaine D. Sun
Chief Financial Officer, Senior Vice President
Jean-Pierre Bizzari
Independent Director
Bernadette M. Connaughton
Independent Director
Price To Earnings (TTM) | 310.80 |
|---|---|
Price To Sales (TTM) | 32.29 |
Price To Book (MRQ) | 65.19 |
Price To Cash Flow (TTM) | 257.09 |
Total Debt To Equity (MRQ) | 397.66 |
LT Debt To Equity (MRQ) | 397.66 |
Return on Investment (TTM) | 5.67 |
Return on Equity (TTM) | 4.81 |
Shares in Danish biotech firm Genmab <GMAB.CO> fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson <JNJ.N> over royalty payments for its key cancer drug.
* HALOZYME TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN
* HALOZYME TO RECEIVE $15 MILLION MILESTONE PAYMENT FROM JANSSEN
* Q1 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA
* JANSSEN SUBMITS NDA IN JAPAN FOR DARATUMUMAB SUBCUTANEOUS FORMULATION UTILIZING HALOZYME'S ENHANZE TECH FOR PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:
* ARTISAN PARTNERS LIMITED PARTNERSHIP REPORTS 10.5% PASSIVE STAKE IN HALOZYME THERAPEUTICS INC AS OF MARCH 31- SEC FILING Source text : (https://bit.ly/34pGO5F) Further company coverage:
* HALOZYME ANNOUNCES FDA HAS ACCEPTED BIOLOGICS LICENSE APPLICATION FOR FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING ENHANZE® TECHNOLOGY
* HALOZYME THERAPEUTICS INC - ELAINE D. SUN HAS BEEN APPOINTED SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE MARCH 2, 2020
* HALOZYME LICENSES NEW ENHANZE TARGETS FOR $25 MILLION UPFRONT PAYMENT, FUTURE MILESTONES AND ROYALTIES
* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S
* HALOZYME THERAPEUTICS INC SAYS CEO HELEN I. TORLEY'S 2017 TOTAL COMPENSATION WAS $5.18 MILLION VERSUS $4.85 MILLION IN 2016 – SEC FILING Source text - https://bit.ly/2udFEM8 Further company coverage:
* REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION Source text for Eikon: Further company coverage:
* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.